17 January 2012 - US Array BioPharma Inc (NASDAQ:ARRY) said on Monday its chief executive officer and director Robert E Conway had left the company after 12 years of service.

The CEO resigned for personal reasons.

Array BioPharma has appointed board chairman Kyle Lefkoff as interim head until a permanent replacement is found. The company will seek a leader to push its products from the clinic to the market.

The biopharmaceutical firm is focused on the discovery, development and commercialisation of targeted small-molecule drugs to treat cancer and inflammatory diseases. The company has nine drugs in Phase II clinical trials and USD3.4bn (EUR2.7bn) in potential milestone payments under its partnerships.

(USD1 = EUR0.781)